Vitamin Shoppe estimates and price target raised at JPMorgan JPMorgan believes Vitamin Shoppe's acceleration in footage growth and improvements in merchandising has made the company's story more compelling. The firm raised its 2013 earnings estimates above consensus and upped its price target for shares to $73 from $69 while keeping an Overweight rating on the stock.
Vitamin Shoppe cuts FY15 EPS to $2.05-$2.25 from $2.36-$2.46, consensus $2.40 Cuts FY15 revenue growth to 6%-8% from approximately 10%, consensus $1.32B. Sees FY15 total comparable sales growth, including ecommerce, in low single digits. Expects approximately 60 new stores in 2015. The updated guidance is in view of Q1 results and recent trends.